Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden

Published:2023-12-13 Issue: Volume: Page:
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Polyzoi Maria,Ekman Mattias,Reithmeier Anja,Jacob Johanna,Karlsson Emma,Bertranou Evelina,Linderholm Barbro,Hettle Robert^ORCID

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s41669-023-00457-4.pdf

Reference78 articles.

1. Socialstyrelsen och Cancerfonden. Cancer i siffror 2018:populärvetenskapliga fakta om cancer. 2018 29/11/2022].

2. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. Lyon: International agency for research on cancer; 2020.

3. Socialstyrelsen. Statistik om cancer: Bilaga—Tabeller—Statistik om nyupptäckta cancerfall 2021. 2021 29/11/2022].

4. National Quality Registry for Breast Cancer (NKBC). Antal bröstcancerfall Bland alla anmälda fall. Diagnosår: 2022. 2022 29/11/2022].

5. American Joint Committee on Cancer (AJCC). AJCC cancer staging manual. 8th ed. Cham: Springer; 2017.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP